

DAFTAR PUSTAKA

- A, Morissan M. 2014. Metode Penelitian Survei. Jakarta: Kencana
- Abdulhak, A. A. Bin *et al.* 2020. Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcome of COVID-19 : A Systematic Review and Meta-analysis. pp. 1–22.
- Abraham, H. M. A., White, C. M. and White, W. B. 2015. The Comparative Efficacy and Safety of the Angiotensin Receptor Blockers in the Management of Hypertension and Other Cardiovascular Diseases. *Drug Safety*, 38(1), pp. 33–54. doi: 10.1007/s40264-014-0239-7.
- Agarwal, N. and Dewan, P. 2016. Writing a review article: Making sense of the jumble. *Indian Pediatrics*, 53(8), pp. 715–720. doi: 10.1007/s13312-016-0915-z.
- Amat-Santos, I. J. *et al.* 2020. Ramipril in High-Risk Patients With COVID-19. *Journal of the American College of Cardiology*, 76(3), pp. 268–276. doi: 10.1016/j.jacc.2020.05.040.
- Ancion, A. *et al.* 2019. A Review of the Role of Bradykinin and Nitric Oxide in the Cardioprotective Action of Angiotensin-Converting Enzyme Inhibitors: Focus on Perindopril. *Cardiology and Therapy*, 8(2), pp. 179–191. doi: 10.1007/s40119-019-00150-w.
- Aromataris, E. and Pearson, A. 2014. The systematic review: An overview. *American Journal of Nursing*, 114(3), pp. 53–58. doi: 10.1097/01.NAJ.0000444496.24228.2c.
- Bansal, M. 2020. Cardiovascular disease and COVID-19. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*. Elsevier Ltd, 14(3), pp. 247–250. doi: 10.1016/j.dsx.2020.03.013.
- Barrett, K. E. *et al.* 2016. *Ganong's Review of Medical Physiology*. Edisi 25. Amerika : McGraw-Hill Education.
- Bonow, R. O. *et al.* 2011. *Heart Disease Braunwald ' S, American Journal of Hypertension*.
- Brunner, H. R. 2002. The new oral angiotensin II antagonist olmesartan medoxomil: A concise overview. *Journal of Human Hypertension*, 16, pp. S13–S16. doi:

10.1038/sj.jhh.1001391.

- Brunton, L. L., Hilal-Dandan, R. and Knollmann, B. C. 2018. *Goodman & Gillman's The Pharmacological Basis of Therapeutics*, McGraw-Hill Education. doi: 10.1017/CBO9781107415324.004.
- Burhan, E. *et al.* 2020. Pedoman Tatalaksana COVID-19. Jakarta : Perhimpunan Dokter Paru Indonesia, Perhimpunan Dokter Spesialis Kardiovaskular Indonesia, Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia, Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia, Ikatan Dokter Anak Indonesia.
- Burhan, E. *et al.* 2020. Pneumonia COVID-19, Diagnosis & Penatalaksanaan di Indonesia. Jakarta : Perhimpunan Dokter Paru Indonesia.
- Burnier, M. 2009. Telmisartan: A different angiotensin II receptor blocker protecting a different population?. *Journal of International Medical Research*, 37(6), pp. 1662–1679. doi: 10.1177/147323000903700602.
- Burnier, M. *et al.* 2011. Long-term use and tolerability of irbesartan for control of hypertension. *Integrated Blood Pressure Control*, p. 17. doi: 10.2147/ibpc.s12211.
- Choi, Hee Kyoung *et al.* 2020. ARB/ACEI use and severe COVID-19: a nationwide case-control study. *medrxiv.org*. doi: 10.1101/2020.06.12.20129916.
- Chung, M. K. *et al.* 2020. SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy. *EBioMedicine*. Elsevier B.V. doi: 10.1016/j.ebiom.2020.102907.
- Clerkin, K. J. *et al.* 2020. Coronavirus disease 2019 (COVID-19) and Cardiovascular Disease. *Research in Cardiovascular Medicine*. doi: 10.4103/rcm.rcm_9_20.
- Da Cunha, V. *et al.* 2005. Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. *Atherosclerosis*, 178(1), pp. 9–17. doi: 10.1016/j.atherosclerosis.2004.08.023.
- Deget, F. and Brogden, R. N. 1991. Cilazapril: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in Cardiovascular Disease. *Drugs*, 41(5), pp. 799–820. doi: 10.2165/00003495-199141050-00008.
- Dézsi, C. A. 2016. The different therapeutic choices with ARBs. Which one to give? When? Why?. *American Journal of Cardiovascular Drugs*, 16(4), pp. 255–266. doi: 10.1007/s40256-016-0165-4.

- Enzyme, A. C. E. A. *et al.* 2020. The Pediatric Perspective. 2(Angiotensin II), pp. 16–22. doi: 10.1161/HYPERTENSIONAHA.120.15291.
- Ferrario, C. M. *et al.* 2005. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. *Circulation*, 111(20), pp. 2605–2610. doi: 10.1161/CIRCULATIONAHA.104.510461.
- Gambo, J. L. *et al.* 2012. Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis. *Journal of the American Society of Nephrology*, 23(2), pp. 334–342. doi: 10.1681/ASN.2011030287.
- Gillespie, E. L. *et al.* 2005. Reviews / Commentaries / ADA Statements The Impact of ACE Inhibitors or Angiotensin II Type 1 Receptor Blockers on the Development of New-Onset Type. *Diabetes Care*, 28(9), pp. 2261–2266. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16123505>.
- Golias, C. *et al.* 2007. The kinin system-bradykinin: Biological effects and clinical implications. Multiple role of the kinin system-bradykinin. *Hippokratia*, 11(3), pp. 124–128.
- Goyal A, Cusick AS, Thielemier B. ACE Inhibitors. 2020. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK430896/>
- Gunawan, Sulistia Gan. *et al.* 2016. Farmakologi dan Terapi Edisi 6. Jakarta: Badan Penerbit FKUI.
- Hall, J. E. 2011. Guyton and Hall Textbook of Medical Physiology. Edisi 12. Amerika Serikat : Elsevier.
- Henry, C. *et al.* 2018. Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia. *Baylor University Medical Center Proceedings*. Taylor & Francis, 31(4), pp. 419–423. doi: 10.1080/08998280.2018.1499293.
- Huang, C. *et al.* 2020. Articles Clinical features of patients infected with 2019 novel coronavirus in Wuhan , China. pp. 497–506. doi: 10.1016/S0140-6736(20)30183-5.
- Hussain, M. *et al.* 2020. Structural variations in human ACE2 may influence its binding with SARS - CoV - 2 spike protein. (March). doi: 10.1002/jmv.25832.

- Ingraham, N. E. *et al.* 2020. Understanding the Renin-Angiotensin-Aldosterone-SARS-CoV-Axis: A Comprehensive Review. *The European respiratory journal*. doi: 10.1183/13993003.00912-2020.
- Ip, A. *et al.* 2020. Hypertension and Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. *medrxiv.org*. doi: 10.1101/2020.04.24.20077388.
- Jaimes, J. A., Millet, J. K. and Whittaker, G. R. 2020. iScience II Proteolytic Cleavage of the SARS-CoV-2 Spike Protein and the Role of the Novel S1 / S2 Site Spike Protein and the Role of the Novel S1 / S2 Site. *ISCIENCE*. Elsevier Inc., 23(6), p. 101212. doi: 10.1016/j.isci.2020.101212.
- Joanna Briggs Institute. 2020. Checklist for Case Control Studies. Adelaide: Joanna Briggs Institute.
- Joanna Briggs Institute. 2020. Checklist for Cohort Studies. Adelaide: Joanna Briggs Institute.
- Joanna Briggs Institute. 2020. Checklist for Randomized Controlled Trials. Adelaide: Joanna Briggs Institute.
- Judson, G. L., Kelemen, B. W. and Njoroge, J. N. 2020. Cardiovascular Implications and Therapeutic Considerations in COVID-19 Infection. *Cardiology and Therapy*. Springer Healthcare. doi: 10.1007/s40119-020-00184-5.
- Jung, S.-Y. *et al.* 2020. Association of renin-angiotensin-aldosterone system inhibitors with COVID-19-related outcomes in Korea: a nationwide population-based cohort study. *Clinical Infectious Diseases*, 2019. doi: 10.1093/cid/ciaa624.
- Kai, H. and Kai, M. 2020. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors—lessons from available evidence and insights into COVID-19. *Hypertension Research*. Springer US. doi: 10.1038/s41440-020-0455-8.
- Katzung, B. G. 2018. *Basic & Clinical Pharmacology*. Edisi 14. Amerika Serikat : McGraw-Hill Education.
- Khashkhusa, T. R., Chan, J. S. K. and Harky, A. 2020. ACEi and ARB with COVID-19. *Journal of Cardiac Surgery*. 35(6), p. 1388. doi: 10.1111/jocs.14649.
- Kim, J. *et al.* 2017. Effect of Renin-Angiotensin System Blockage in Patients with Acute Respiratory Distress Syndrome : A Retrospective Case Control Study. 29(04), pp. 154–163.

- Kobori, H. *et al.* 2013. Angiotensin II Blockade and Renal Protection. *Current Pharmaceutical Design*, 19(17), pp. 3033–3042. doi: 10.2174/1381612811319170009.
- Kuba, K. *et al.* 2010. Trilogy of ACE2: A peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters. *Pharmacology and Therapeutics*. Elsevier Inc., 128(1), pp. 119–128. doi: 10.1016/j.pharmthera.2010.06.003.
- Lake, M. A. 2020. What we know so far: COVID-19 current clinical knowledge and research. *Clinical Medicine, Journal of the Royal College of Physicians of London*, 20(2), pp. 124–127. doi: 10.7861/clinmed.2019-coron.
- Lam, K. W. *et al.* 2020. Continued in-hospital ACE inhibitor and ARB Use in hypertensive COVID-19 patients is associated with positive clinical outcomes. *The Journal of Infectious Diseases*, 11794, pp. 1–9. doi: 10.1093/infdis/jiaa447.
- Lee, H.-Y. *et al.* 2020. Association of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors on COVID-19-Related Outcome. *SSRN Electronic Journal*, 13. doi: 10.2139/ssrn.3569837.
- Lee, H. W. *et al.* 2020. Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis. *The Korean Journal of Internal Medicine*. doi: 10.3904/kjim.2019.262.
- Li, G., Hu, R. and Zhang, X. 2020. Antihypertensive treatment with ACEI / ARB of patients with COVID- 19 complicated by hypertension. *Hypertension Research*. Springer US, pp. 1–3. doi: 10.1038/s41440-020-0433-1.
- Li, J. *et al.* 2020. Association of Renin-Angiotensin System Inhibitors with Severity or Risk of Death in Patients with Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. *JAMA Cardiology*, 2019, pp. 1–6. doi: 10.1001/jamacardio.2020.1624.
- Lilly, L. S. 2016. *Pathophysiology of Heart Disease*. Wolters Kluwer Health. doi: 10.1136/pgmj.64.757.910-a.
- Lutz, C. *et al.* 2020. COVID-19 preclinical models : human transgenic mice. *Human Genomics*, pp. 1–11.
- Mason, R. J. 2020. Pathogenesis of COVID-19 from a cell biology perspective. *European Respiratory Journal*, 55(4), pp. 9–11. doi: 10.1183/13993003.00607-2020.

- Mbuzi, V., Fulbrook, P. and Jessup, M. 2018. Effectiveness of programs to promote cardiovascular health of Indigenous Australians : a systematic review. *International Journal for Equity in Health*, pp. 1–17.
- Mcmurray, J. J. V *et al.* 2020. Renin – Angiotensin – Aldosterone System Inhibitors in Patients with Covid-19. pp. 1–7.
- Mehra, M. R. *et al.* 2020. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. *New England Journal of Medicine*, pp. 1–8. doi: 10.1056/nejmoa2007621.
- Öztürk, R. 2020. COVID-19: Pathogenesis, Genetic Polymorphism, Clinical Features and Laboratory Findings. *Turkish journal of medical sciences*, pp. 1–20. doi: 10.3906/sag-2005-287.
- Pradhan, A., Tiwari, A. and Sethi, R. 2019. Azilsartan: Current Evidence and Perspectives in Management of Hypertension. *International Journal of Hypertension*, 2019. doi: 10.1155/2019/1824621.
- Prajapati, S. *et al.* 2020. An update on novel COVID-19 pandemic : a battle between humans and virus. (December 2019), pp. 5819–5829.
- Prasad, P. P. *et al.* 2002. Pharmacokinetics of multiple doses of valsartan in patients with heart failure. *Journal of Cardiovascular Pharmacology*, 40(5), pp. 801–807. doi: 10.1097/00005344-200211000-00018.
- Ranard, L. S. *et al.* 2020. Approach to Acute Cardiovascular Complications in COVID-19 Infection. *Circulation: Heart Failure*. Ovid Technologies (Wolters Kluwer Health), 13(7). doi: 10.1161/circheartfailure.120.007220.
- Rang, H. P. *et al.* 2015. Rang & Dale’s Pharmacology. Edisi 8. London : Churchill Livingstone.
- Rico-mesa, J. S. *et al.* 2020. Outcomes in Patients with COVID-19 Infection Taking ACEI / ARB. *Current Cardiology Reports*, pp. 20–23.
- Rossi, G. P., Sanga, V. and Barton, M. 2020. Potential harmful effects of discontinuing ace-inhibitors and arbs in covid-19 patients. *eLife*, 9, pp. 1–8. doi: 10.7554/eLife.57278.
- Sarvepalli, D. 2020. Coronavirus Disease 2019 : A Comprehensive Review of Etiology , Pathogenesis , Diagnosis , and Ongoing Clinical Trials. 12(5). doi: 10.7759/cureus.8076.

- Satuan Tugas Penanganan COVID-19. 2021. Satgas Penanganan COVID-19, diakses 7 Januari 2021 pukul 10:10 WIB.
<https://covid19.go.id/>
- Shamseer, L. *et al.* 2015. Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015: Elaboration and explanation. *BMJ (Online)*, 349(January), pp. 1–25. doi: 10.1136/bmj.g7647.
- Sharma, A. *et al.* 2020. Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): A global pandemic and treatments strategies. (January).
- Sherwood, Lauralee. 2014. Fisiologi Manusia dari Sel ke Sistem. Edisi 8. Jakarta: EGC
- Sica, D. 2001. Pharmacology and clinical efficacy of angiotensin receptor blockers. *American Journal of Hypertension*, 14(11), pp. S242–S247. doi: 10.1016/s0895-7061(01)02134-3.
- Sica, D. A. 2004. Angiotensin-converting enzyme inhibitors side effects--physiologic and non-physiologic considerations. *Journal of clinical hypertension (Greenwich, Conn.)*, 6(7), pp. 410–416. doi: 10.1111/j.1524-6175.2004.02866.x.
- Soehnlein, O. *et al.* 2005. ACE inhibition lowers angiotensin-II-induced monocyte adhesion to HUVEC by reduction of p65 translocation and AT1 expression. *Journal of Vascular Research*, 42(5), pp. 399–407. doi: 10.1159/000087340.
- Taylor, A. A., Siragy, H. and Nesbitt, S. 2011. Angiotensin receptor blockers: Pharmacology, efficacy, and safety. *Journal of Clinical Hypertension*, 13(9), pp. 677–686. doi: 10.1111/j.1751-7176.2011.00518.x.
- Thierry, A. R. and Roch, B. 2020. SARS-CoV2 may evade innate immune response , causing uncontrolled neutrophil extracellular traps formation and multi-organ failure. pp. 1295–1300.
- Tikellis, C. and Thomas, M. C. 2012. Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease', *International Journal of Peptides*. doi: 10.1155/2012/256294.
- Trifirò, G. *et al.* 2020. Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19). 43, pp. 507–509. doi: 10.1007/s40264-020-00935-2.
- Verdecchia, P. *et al.* 2020. The pivotal link between ACE2 deficiency and SARS-CoV-2

infection. (January).

- Wang, J. *et al.* 2020. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. (April), pp. 1–25. doi: 10.1002/JLB.3COVR0520-272R.
- Widmaier, E. P., Raff, H. and Strang, K. T. 2019. *Vander's Human Physiology, McGraw-Hill Education*. doi: 10.1017/CBO9781107415324.004.
- World Health Organization, 2021. WHO Coronavirus Disease (COVID-19) Dashboard, diakses 7 Januari 2021 pukul 10:08 WIB
<https://covid19.who.int/>
- Wrotek, S. *et al.* 2020. New insights into the role of glutathione in the mechanism of fever. *International Journal of Molecular Sciences*, 21(4). doi: 10.3390/ijms21041393.
- Yang, G. *et al.* 2020. Effects of ARBs and ACEIs on virus infection, inflammatory status and clinical outcomes in COVID-19 patients with hypertension: a single center retrospective study. *Am Heart Assoc*. Lippincott Williams and Wilkins, pp. 51–58. doi: 10.1161/HYPERTENSIONAHA.120.15143.
- Yehualashet, A. S. and Belachew, T. F. 2020. ACEIs and ARBs and Their Correlation with COVID-19: A Review. *Infection and Drug Resistance*, Volume 13, pp. 3217–3224. doi: 10.2147/idr.s264882.
- Yuki, K., Fujiogi, M. and Koutsogiannaki, S. 2020. COVID-19 pathophysiology: A review. (January).
- Zhang, P., Zhu, L., Cai, J., Lei, F., Qin, J. J., *et al.* 2020. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality among Patients with Hypertension Hospitalized with COVID-19. *Circulation Research*, 126(12), pp. 1671–1681. doi: 10.1161/CIRCRESAHA.120.317134.
- Zhang, X. *et al.* 2017. Management of Hypertension Using Olmesartan Alone or in Combination. *Cardiology and Therapy*. Springer Healthcare, 6(1), pp. 13–32. doi: 10.1007/s40119-017-0087-5.
- Zhang, Y. *et al.* 2020. New understanding of the damage of SARS-CoV-2 infection outside the respiratory system. *Biomedicine and Pharmacotherapy*. Elsevier, 127(April), p. 110195. doi: 10.1016/j.biopha.2020.110195.

Zhou, X., Zhu, J. and Xu, T. 2020. Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin–angiotensin system inhibitors. *Clinical and Experimental Hypertension*. Taylor & Francis, 00(00), pp. 1–5. doi: 10.1080/10641963.2020.1764018.